Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) EBT: 2009-2024

Historic EBT for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Dec 2024 value amounting to -$22.9 million.

  • Vanda Pharmaceuticals' EBT fell 354.68% to -$28.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$107.1 million, marking a year-over-year decrease of 492.44%. This contributed to the annual value of -$22.9 million for FY2024, which is 461.59% down from last year.
  • According to the latest figures from FY2024, Vanda Pharmaceuticals' EBT is -$22.9 million, which was down 461.59% from $6.3 million recorded in FY2023.
  • In the past 5 years, Vanda Pharmaceuticals' EBT registered a high of $42.4 million during FY2021, and its lowest value of -$22.9 million during FY2024.
  • For the 3-year period, Vanda Pharmaceuticals' EBT averaged around -$1.8 million, with its median value being $6.3 million (2023).
  • Per our database at Business Quant, Vanda Pharmaceuticals' EBT surged by 33.83% in 2021 and then plummeted by 461.59% in 2024.
  • Yearly analysis of 5 years shows Vanda Pharmaceuticals' EBT stood at $31.7 million in 2020, then soared by 33.83% to $42.4 million in 2021, then plummeted by 73.33% to $11.3 million in 2022, then plummeted by 43.90% to $6.3 million in 2023, then crashed by 461.59% to -$22.9 million in 2024.